Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors

Clinical trial NCT04053673 · UNKNOWN

Trial details

NCT number: NCT04053673
Sponsor: Ribon Therapeutics, Inc.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor, Adult

Start date: 2019-08-01
Primary completion: 2023-06-30
Enrollment: 130

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.